---
figid: PMC6966427__cancers-11-01834-g001
figtitle: B-cell receptor pathway
organisms:
- NA
pmcid: PMC6966427
filename: cancers-11-01834-g001.jpg
figlink: pmc/articles/PMC6966427/figure/cancers-11-01834-f001/
number: F1
caption: 'Overview of the B-cell receptor pathway. Shown are the B cell receptor (BCR)
  and signaling intermediates engaged in signal propagation following binding of the
  BCR to antigen. Numbers indicate inhibitors targeting particular components of the
  BCR signaling: (1) ibrutinib; (2) acalabrutinib; (3) zanabrutinib; (4) tirabrutinib;
  (5) GDC-0853; (6) vecabrutinib; (7) LOXO-305; (8) ARQ-531; (9) venetoclax; (10)
  entospletinib; (11) cerdulatinib; (12) duvelisib; (13) idelalisib; (14) selinexor;
  (15) CC-115. See main text for details. Bcl-2, B-cell lymphoma 2 protein; BLNK,
  B-cell linker protein; BTK, Bruton tyrosine kinase; CBM, CARD11–BCL-10–MALT1; Cyt.C,
  cytochrome C; DAG, diacylglycerol; ERK, extracellular signal–regulated kinase; IKK,
  inhibitor of NF-κB kinase; IRAKs, interleukin-1 receptor-associated kinases; MEK,
  mitogen-activated protein kinase; mTOR, mammalian target of rapamycin; MYD88, myeloid
  differentiation primary response 88; NF-κB, nuclear factor-κB; PI3K, phosphoinositide
  3-kinase; PKCβ, protein kinase Cβ; PLCγ, phospholipase Cγ; SYK, spleen tyrosine
  kinase; TLR9, toll-like receptor 9; TRAF6, TNF receptor-associated factor 6; XPO1,
  exportin 1.'
papertitle: Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia.
reftext: Bartosz Puła, et al. Cancers (Basel). 2019 Dec;11(12):1834.
year: '2019'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.957277
figid_alias: PMC6966427__F1
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC6966427__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6966427__cancers-11-01834-g001.html
  '@type': Dataset
  description: 'Overview of the B-cell receptor pathway. Shown are the B cell receptor
    (BCR) and signaling intermediates engaged in signal propagation following binding
    of the BCR to antigen. Numbers indicate inhibitors targeting particular components
    of the BCR signaling: (1) ibrutinib; (2) acalabrutinib; (3) zanabrutinib; (4)
    tirabrutinib; (5) GDC-0853; (6) vecabrutinib; (7) LOXO-305; (8) ARQ-531; (9) venetoclax;
    (10) entospletinib; (11) cerdulatinib; (12) duvelisib; (13) idelalisib; (14) selinexor;
    (15) CC-115. See main text for details. Bcl-2, B-cell lymphoma 2 protein; BLNK,
    B-cell linker protein; BTK, Bruton tyrosine kinase; CBM, CARD11–BCL-10–MALT1;
    Cyt.C, cytochrome C; DAG, diacylglycerol; ERK, extracellular signal–regulated
    kinase; IKK, inhibitor of NF-κB kinase; IRAKs, interleukin-1 receptor-associated
    kinases; MEK, mitogen-activated protein kinase; mTOR, mammalian target of rapamycin;
    MYD88, myeloid differentiation primary response 88; NF-κB, nuclear factor-κB;
    PI3K, phosphoinositide 3-kinase; PKCβ, protein kinase Cβ; PLCγ, phospholipase
    Cγ; SYK, spleen tyrosine kinase; TLR9, toll-like receptor 9; TRAF6, TNF receptor-associated
    factor 6; XPO1, exportin 1.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - BCR
  - RN7SL263P
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - SYK
  - BLNK
  - AKT1
  - AKT2
  - AKT3
  - BTK
  - TLR9
  - MTOR
  - PLCG2
  - MYD88
  - IKBKG
  - CHUK
  - IKBKB
  - PRRT2
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - PRKCG
  - PRKCH
  - PRKCI
  - PRKCQ
  - PRKCZ
  - PRKD3
  - KRAS
  - HRAS
  - NRAS
  - IRAK1
  - IRAK2
  - TRAF6
  - RAF1
  - NFKB1
  - TP53
  - TP63
  - TP73
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - XPO1
  - EPHB2
  - MAPK1
  - MAPK3
  - Ca++
---
